Variable efficacy and dose-limiting toxic effects of BET inhibitors such as thrombocytopenia are commonly observed in preclinical and clinical studies and strongly imply that the discovery of biomarkers that can help predict therapeutic response is a prerequisite for effective and safe treatment using BET inhibitors54. The gene discussed is DNER; the disease is Thrombocytopenia.